AbbVie stock drops 12% on schizophrenia drug setback: should

6 days ago · AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes ABBV on the strength of its pipeline. AbbVie stock pays a healthy …

CouponFollow Extension

12%
OFF

AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should

1 week from now

6 days ago · AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes ABBV on the strength of its pipeline. AbbVie stock pays a healthy …

invezz.com

12%
OFF

AbbVie’s Stock Plummets Over 12% After Schizophrenia Drug Flops …

1 week from now

6 days ago · AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to meet its primary endpoints in the …

yahoo.com

12%
OFF

AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should …

1 week from now

6 days ago · This setback is notable as AbbVie had invested $8.7 billion to acquire the drug, aiming to strengthen its foothold in the schizophrenia market and offset declining sales in its …

talkmarkets.com

12%
OFF

AbbVie's Closely Watched Schizophrenia Drug Fails Two Studies, …

1 week from now

Nov 11, 2024 · AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers …

reuters.com

13%
OFF

AbbVie Stock Drops After New Schizophrenia Drug Fails Trials

1 week from now

Nov 11, 2024 · AbbVie shares fell as much as 13% as of 11:15 a.m. in New York, their biggest intraday drop since March 2020. The stock had gained 29% this year through Friday’s close, …

chicagobusiness.com

$8
OFF

AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia ...

1 week from now

Nov 11, 2024 · AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the …

morningstar.com

12%
OFF

AbbVie Reveals Schizophrenia Setback - LinkedIn

1 week from now

Nov 11, 2024 · AbbVie's experimental schizophrenia drug which it acquired through a $8.7 bln deal of Cerevel last year failed in a pair of mid stage studies and shares slumped over 12% on …

linkedin.com

12%
OFF

Buy, Sell, Or Hold AbbVie Stock? - Forbes

1 week from now

6 days ago · AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat …

forbes.com

10%
OFF

AbbVie Stock: Keep Calm And Buy The Dip - Seeking Alpha

1 week from now

6 days ago · AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. …

seekingalpha.com

12%
OFF

AbbVie Inc. (ABBV) Stock Price, Quote & News - Stock Analysis

1 week from now

3 days ago · AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip? AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage …

stockanalysis.com

11%
OFF

AbbVie Stock Falls 11% In A Month: Should You Buy The Dip?

1 week from now

3 days ago · AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II …

nasdaq.com

$9
OFF

On Wall Street, ‘flat Out’ Failure Of AbbVie Schizophrenia Drug …

1 week from now

Nov 11, 2024 · Through a recent, nearly $9 billion acquisition, AbbVie surged to the front of a new wave of antipsychotic drugs that Wall Street expects to become big sellers.But on Monday, the …

biopharmadive.com

11%
OFF

AbbVie Stock Falls 11% In A Month: Should You Buy The Dip?

1 week from now

3 days ago · AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II …

tradingview.com

FAQs about AbbVie stock drops 12% on schizophrenia drug setback: should Coupon?

Why did AbbVie stock fall 12%?

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to meet its primary endpoints in the company’s Phase II programme. ...

Should you buy AbbVie shares after emraclidine failed?

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robust drug pipeline are bullish going forward. ...

How long does it take to buy AbbVie (ABV) stock?

Takes 2 mins. This setback is notable as AbbVie had invested $8.7 billion to acquire the drug, aiming to strengthen its foothold in the schizophrenia market and offset declining sales in its arthritis segment due to rising competition. Despite the current dip, AbbVie’s stock remains up about 15% from its year-to-date low in late May. ...

Should you buy AbbVie (abbv) shares?

AbbVie (NYSE: ABBV) shares are plummeting as the company's schizophrenia treatment drug reportedly failed to meet its primary endpoint in a late-state study. While certainly a blow, the resulting drop of nearly 10% as I write this appears to be significantly overdone, and I think investors could benefit from buying this dip. ...

Why are Abbvie shares sliding on Monday?

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. ...

Did AbbVie buy cerevel Therapeutics?

AbbVie had acquired the drug through a $8.7 billion takeover of Cerevel Therapeutics last year. Shares of Bristol Myers (BMY.N), which received U.S. approval for a new type of schizophrenia treatment in September, surged 13% to $61.10 in premarket trading. ...